1984

Since 1984, GBC has advanced diagnostics from immunodiagnostics and molecular diagnostics to automated testing and liquid biopsy, continuously innovating to support more accurate testing and better healthcare decisions.

Learn More

Innovating Diagnostics,
Advancing the Future

Building on four decades of diagnostic expertise, GBC is advancing next-generation precision diagnostics across immunodiagnostics, molecular diagnostics and liquid biopsy.

GBC is building three core platforms: CLIA, automated molecular diagnostics and CellBio™ liquid biopsy, while expanding into antimicrobial peptide and healthcare innovation through GBP.

Reveal. Better Life.

Through better diagnostics, we reveal new possibilities.